Cell transplantation models / LNCaP

LNCaP cell transplantation models

Prostate adenocarcinoma (androgen-sensitive)

Classic AR+/PSA+ line (Horoszewicz 1983). s.c. (Lim 1×10⁶ / 0.25 mL Matrigel) and dorsal-lobe orthotopic (Liu 1×10⁶ / 20 μL) are two SOPs—volumes are not interchangeable; no-gel s.c. often fails. Do not copy PC-3 or MDA-MB-231. C4-2 is not parental. RUO.

  1. [1]PMID 6831420 — LNCaP model of human prostatic carcinoma. Cancer Res (1983)
  2. [2]PMID 7681204 — Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate (1993)
  3. [3]PMID 35168543 — Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate. BMC Cancer (2022)
  4. [4]PMID 9108464 — A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res (1997)

SKU: MC-h125 · Disease models · In-vitro spheroid

Protocols(2)

LNCaP subcutaneous xenograft

AR+/PSA+ LNCaP flank s.c. CDX usually needs Matrigel for endocrine/castration pharmacology. This SOP uses Lim: 1×10⁶ + 0.25 mL Matrigel. Sato contrast: same cell number s.c. (100% take in SCID); that abstract does not state μL. Not orthotopic prostate. Do not copy MDA-MB-231’s 2×10⁶ / 100 μL, and do not default 0.25 mL gel to 100 μL.

Open full protocol →

LNCaP orthotopic prostate inoculation (dorsal lobe)

Microscope-guided unilateral dorsal-lobe (DP) injection of parental LNCaP for an AR+ orthotopic tumor. This SOP uses Liu: 1×10⁶ in 20 μL PBS + 50% Matrigel; 3% isoflurane at 0.8 L/min induction. Sato: same cell number orthotopic, SCID take 89%, 12-week nodes 100% and lung micromets 40% (n=10). Not PC-3 anterior-lobe 50 μL no-gel, and not 231’s 2×10⁶ / 100 μL. Wang is fragment SOI, not this needle.

Open full protocol →

Protocol index

Red [Non-metastatic] = local tumorigenesis, not a distant-met endpoint; [Weak metastasis evidence] = poorly supported for parental line—exploratory/negative-control use.

Related

Disclaimer: Research use only (RUO). Not clinical guidance or a substitute for institutional animal SOPs. In vivo work requires ethics approval. Inline [n] maps to each section’s reference list.